Â鶹ѧÉú¾«Æ·°æ

Andrew P. Soisson
( out of 132 reviews )

Andrew P. Soisson, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital North

2K, Gynecology and Mammography
Salt Lake City
801-213-4269

Sugar House Health Center

Salt Lake City
801-581-2000

  • Andrew "Pat" Soisson, MD, is a Professor in the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology at the University of Utah, School of Medicine and a Huntsman Cancer Institute investigator. Dr. Soisson specializes in gynecologic cancers, especially invasive cervical cancer and high risk gynecological surgery. He is also interested in developing a center for treatment of cervical cancer and pre-invasive cervical disease that uses a multidisciplinary approach to study the human papillomavirus and its connection with cervical cancer. Dr. Soisson is the co- primary investigator, with Doctor Theresa Werner, in the Gynecologic Oncology Group, a National Cancer Institute-funded nonprofit organization that promotes excellence in quality and integrity of clinical and basic scientific research. Before joining Huntsman Cancer Institute, he was division director of gynecologic oncology at the West Virginia University Medical Center. Dr. Soisson received his medical degree from Georgetown Medical School in Maryland and completed a fellowship in gynecologic oncology at Duke University Medical Center.

    Dr. Soisson is an avid hiker and utilizes this form of exercise for fitness and mental well-being. He is an advocate for these activities and promotes them to his patients and their families who are dealing with the physical and emotional stress associated with gynecologic cancers.

    Specialties

    Board Certification

    National Board of Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 132 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 31, 2024
    SUGAR HOUSE HEALTH CENTER

    El Dr. Andrew P Soisson, para mi a sido mi ángel que Dios me puso en el camino desde el primer día en que comencé este camino de esta enfermedad. Es un maravilloso ser humano lleno de cortesía, amor por sus pacientes, le tengo mucha confianza por ser uno de mis Oncólogos. Dios le bendiga siempre Dr. Soisson.

    July 31, 2024
    SUGAR HOUSE HEALTH CENTER

    He's a very caring doctor and listening to my feedings about my concerns.

    July 25, 2024
    SUGAR HOUSE HEALTH CENTER

    I am so happy and blessed that god sent dr Soisson to be my doctor I will always be grateful for him my family that have met him love him too, thank you dr Soisson

    July 18, 2024
    SUGAR HOUSE HEALTH CENTER

    Very nice very thorough very knowledgeable. Appreciate his service.

    June 27, 2024
    HUNTSMAN CANCER CENTER

    Dr Soisson is compassionate, positive, and knowledgeable.

    June 25, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Soisson is an amazing Dr. as well as a great person. He truly cares about his patients and their total well being. I would 100% recommend his anyone looking for this type of Dr.

    June 21, 2024
    SUGAR HOUSE HEALTH CENTER

    Very helpful; looked at the big picture, informed of options and helped me understand reasoning.

    June 19, 2024
    SUGAR HOUSE HEALTH CENTER

    Great physician with excellent listening skills and real concern

    May 24, 2024
    HUNTSMAN CANCER CENTER

    Dr. Soisson is the best!

    See More Patient Comments

  • Andrew "Pat" Soisson, MD, is a Professor in the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology at the University of Utah, School of Medicine and a Huntsman Cancer Institute investigator. Dr. Soisson specializes in gynecologic cancers, especially invasive cervical cancer and high risk gynecological surgery. He is also interested in developing a center for treatment of cervical cancer and pre-invasive cervical disease that uses a multidisciplinary approach to study the human papillomavirus and its connection with cervical cancer. Dr. Soisson is the co- primary investigator, with Doctor Theresa Werner, in the Gynecologic Oncology Group, a National Cancer Institute-funded nonprofit organization that promotes excellence in quality and integrity of clinical and basic scientific research. Before joining Huntsman Cancer Institute, he was division director of gynecologic oncology at the West Virginia University Medical Center. Dr. Soisson received his medical degree from Georgetown Medical School in Maryland and completed a fellowship in gynecologic oncology at Duke University Medical Center.

    Dr. Soisson is an avid hiker and utilizes this form of exercise for fitness and mental well-being. He is an advocate for these activities and promotes them to his patients and their families who are dealing with the physical and emotional stress associated with gynecologic cancers.

    Board Certification and Academic Information

    Academic Departments Obstetrics & Gynecology -Primary
    Academic Divisions Gynecological Oncology
    Board Certification
    National Board of Medical Examiners

    Education history

    Fellowship Gynecolgic Oncology - Duke University Medical Center Fellow
    OB/GYN - Madigan Army Medical Center Resident
    Internship OB/GYN - Madigan Army Medical Center Intern
    Medicine - Georgetown University M.D.
    Undergraduate Biology - St. Vincent College B.S.

    Selected Publications

    Journal Article

    1. Seger HM, Soisson AP, Dodson MK, Rowe KG, Cannon-Albright LA (2011). Familial clustering of endometrial cancer in a well-defined population. Gynecol Oncol, 122(1), 75-8. ()
    2. Eller AG, Bennett MA, Sharshiner M, Masheter C, Soisson AP, Dodson M, Silver RM (2011). Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. Obstet Gynecol, 117(2 Pt 1), 331-7. ()
    3. Brown AP, Neeley ES, Werner T, Soisson AP, Burt RW, Gaffney DK (2010). A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations. Int J Radiat Oncol Biol Phys, 78(1), 127-35. ()
    4. Fuhrman CB, Kilgore J, LaCoursiere YD, Lee CM, Milash BA, Soisson AP, Zempolich KA (2008). Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition. Gynecol Oncol, 110(1), 93-8. ()
    5. Soisson AP, Reed E, Brown P, Ducatman B, Armistead J, Kennedy S, Wang W, Kramer P, Rose S (2008). Self-test device for cytology and HPV testing in rural Appalachian women: an evaluation. J Reprod Med, 53(6), 441-8. ()
    6. Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, Dodson MK, Tolley HD, Green CL, Zempolich KA (2006). Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res, 12(1), 250-6. ()
    7. Belcastro M, Miller MR, Flynn DC, Soisson AP (2004). C/EBPbeta activity and HPV-16 E6/E7 mRNA expression are not altered by imiquimod (ALDARA) in human cervical cancer cells in vitro. Gynecol Oncol, 92(2), 660-8. ()
    8. Kamat AA, Kramer P, Soisson AP (2003). Superiority of electrocautery over the suture method for achieving cervical cone bed hemostasis. Obstet Gynecol, 102(4), 726-30. ()
    9. Kamat A, Kramer P, Soisson AP (2002). Cephalic vein cutdown for inserting indwelling subclavian vein catheters in gynecologic oncology patients. W V Med J, 98(1), 15-7. ()

    Review

    1. Hunn J, Dodson MK, Webb J, Soisson AP (2009). Endometrial cancer--current state of the art therapies and unmet clinical needs: the role of surgery and preoperative radiographic assessment. [Review]. Adv Drug Deliv Rev, 61(10), 890-5. ()

    Editorial

    1. Gaffney DK, Soisson AP (2010). Simple or complex: optimal therapy for cancer of the cervix. Gynecol Oncol, 119(3), 401-3. ()